Search

Your search keyword '"Johanson, Per"' showing total 299 results
Start Over Author "Johanson, Per" Publication Year Range Last 50 years
299 results on '"Johanson, Per"'

4. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF

Author

Docherty, Kieran F., Jhund, Pardeep S., Anand, Inder, Bengtsson, Olof, Böhm, Michael, de Boer, Rudolf A., DeMets, David L., Desai, Akshay S., Drozdz, Jaroslaw, Howlett, Jonathan, Inzucchi, Silvio E., Johanson, Per, Katova, Tzvetana, Køber, Lars, Kosiborod, Mikhail N., Langkilde, Anna Maria, Lindholm, Daniel, Martinez, Felipe A., Merkely, Béla, Nicolau, Jose C., O’Meara, Eileen, Ponikowski, Piotr, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D., Tereshchenko, Sergey, Verma, Subodh, and McMurray, John J.V.

Published
2020
Full Text
View/download PDF

6. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58

Author

Bonaca, Marc P., Wiviott, Stephen D., Zelniker, Thomas A., Mosenzon, Ofri, Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Goodrich, Erica L., De Mendonca Furtado, Remo Holanda, Wilding, John P.H., Cahn, Avivit, Gause-Nilsson, Ingrid A.M., Johanson, Per, Fredriksson, Martin, Johansson, Peter A., Langkilde, Anna Maria, Raz, Itamar, and Sabatine, Marc S.

Published
2020
Full Text
View/download PDF

8. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

Author

Kato, Eri T., Silverman, Michael G., Mosenzon, Ofri, Zelniker, Thomas A., Cahn, Avivit, Furtado, Remo H.M., Kuder, Julia, Murphy, Sabina A., Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P.H., Bonaca, Marc P., Ruff, Christian T., Desai, Akshay S., Goto, Shinya, Johansson, Peter A., Gause-Nilsson, Ingrid, Johanson, Per, Langkilde, Anna Maria, Raz, Itamar, Sabatine, Marc S., and Wiviott, Stephen D.

Published
2019
Full Text
View/download PDF

15. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes

Author

Berg, David D., primary, Wiviott, Stephen D., primary, Scirica, Benjamin M., primary, Zelniker, Thomas A., primary, Goodrich, Erica L., primary, Jarolim, Petr, primary, Mosenzon, Ofri, primary, Cahn, Avivit, primary, Bhatt, Deepak L., primary, Leiter, Lawrence A., primary, McGuire, Darren K., primary, Wilding, John P.H., primary, Johanson, Per, primary, Langkilde, Anna Maria, primary, Raz, Itamar, primary, Braunwald, Eugene, primary, Sabatine, Marc S., primary, and Morrow, David A., primary

Published
2021
Full Text
View/download PDF

16. Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial

Author

Bergmark, Brian A., primary, Bhatt, Deepak L., additional, Steg, P. Gabriel, additional, Budaj, Andrzej, additional, Storey, Robert F., additional, Gurmu, Yared, additional, Kuder, Julia F., additional, Im, KyungAh, additional, Magnani, Giulia, additional, Oude Ophuis, Ton, additional, Hamm, Christian, additional, Špinar, Jindřich, additional, Kiss, Robert G., additional, Van de Werf, Frans J., additional, Montalescot, Gilles, additional, Johanson, Per, additional, Braunwald, Eugene, additional, Sabatine, Marc S., additional, and Bonaca, Marc P., additional

Published
2021
Full Text
View/download PDF

20. Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long‐Term Ticagrelor in Stable Patients With Prior Myocardial Infarction

Author

Magnani, Giulia, primary, Ardissino, Diego, additional, Im, KyungAh, additional, Budaj, Andrzej, additional, Storey, Robert F., additional, Steg, P. Gabriel, additional, Bhatt, Deepak L., additional, Cohen, Marc, additional, Oude Ophius, Ton, additional, Goudev, Assen, additional, Parkhomenko, Alexander, additional, Kamensky, Gabriel, additional, Angiolillo, Dominick J., additional, López‐Sendón, José, additional, Johanson, Per, additional, Braunwald, Eugene, additional, Sabatine, Marc S., additional, and Bonaca, Marc P., additional

Published
2021
Full Text
View/download PDF

21. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction:A Prespecified Analysis of DAPA-HF

Author

Docherty, Kieran F, Jhund, Pardeep S, Anand, Inder, Bengtsson, Olof, Böhm, Michael, de Boer, Rudolf A, DeMets, David L, Desai, Akshay S, Drozdz, Jaroslaw, Howlett, Jonathan, Inzucchi, Silvio E, Johanson, Per, Katova, Tzvetana, Køber, Lars, Kosiborod, Mikhail N, Langkilde, Anna Maria, Lindholm, Daniel, Martinez, Felipe A, Merkely, Béla, Nicolau, Jose C, O'Meara, Eileen, Ponikowski, Piotr, Sabatine, Marc S, Sjöstrand, Mikaela, Solomon, Scott D, Tereshchenko, Sergey, Verma, Subodh, McMurray, John J V, Docherty, Kieran F, Jhund, Pardeep S, Anand, Inder, Bengtsson, Olof, Böhm, Michael, de Boer, Rudolf A, DeMets, David L, Desai, Akshay S, Drozdz, Jaroslaw, Howlett, Jonathan, Inzucchi, Silvio E, Johanson, Per, Katova, Tzvetana, Køber, Lars, Kosiborod, Mikhail N, Langkilde, Anna Maria, Lindholm, Daniel, Martinez, Felipe A, Merkely, Béla, Nicolau, Jose C, O'Meara, Eileen, Ponikowski, Piotr, Sabatine, Marc S, Sjöstrand, Mikaela, Solomon, Scott D, Tereshchenko, Sergey, Verma, Subodh, and McMurray, John J V

Abstract

BACKGROUND: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure), dapagliflozin, added to guideline-recommended therapies, reduced the risk of mortality and heart failure (HF) hospitalization. We examined the frequency and significance of episodes of outpatient HF worsening, requiring the augmentation of oral therapy, and the effects of dapagliflozin on these additional events.METHODS: Patients in New York Heart Association functional class II to IV, with a left ventricular ejection fraction ≤40% and elevation of NT-proBNP (N-terminal pro-B-type natriuretic peptide), were eligible. The primary outcome was the composite of an episode of worsening HF (HF hospitalization or an urgent HF visit requiring intravenous therapy) or cardiovascular death, whichever occurred first. An additional prespecified exploratory outcome was the primary outcome plus worsening HF symptoms/signs leading to the initiation of new, or the augmentation of existing, oral treatment.RESULTS: Overall, 36% more patients experienced the expanded, in comparison with the primary, composite outcome. In the placebo group, 684 of 2371 (28.8%) patients and, in the dapagliflozin group, 527 of 2373 (22.2%) participants experienced the expanded outcome (hazard ratio, 0.73 [95% CI, 0.65-0.82]; P<0.0001). Each component of the composite was reduced significantly by dapagliflozin. Over the median follow-up of 18.2 months, the number of patients needed to treat with dapagliflozin to prevent 1 experiencing an episode of fatal or nonfatal worsening was 16. Among the 4744 randomly assigned patients, the first episode of worsening was outpatient augmentation of treatment in 407 participants (8.6%), an urgent HF visit with intravenous therapy in 20 (0.4%), HF hospitalization in 489 (10.3%), and cardiovascular death in 295 (6.2%). The adjusted risk of death from any cause (in comparison with no event) after an outpatient worsening was hazard ratio, 2.67 (95% CI

Published
2020

22. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients with Heart Failure with and Without Diabetes

Author

Petrie, Mark C., Verma, Subodh, Docherty, Kieran F., Inzucchi, Silvio E., Anand, Inder, Bělohlávek, Jan, Böhm, Michael, Chiang, Chern En, Chopra, Vijay K., De Boer, Rudolf A., Desai, Akshay S., Diez, Mirta, Drozdz, Jaroslaw, Dukát, Andre, Ge, Junbo, Howlett, Jonathan, Katova, Tzvetana, Kitakaze, Masafumi, Ljungman, Charlotta E.A., Merkely, Béla, Nicolau, Jose C., O'Meara, Eileen, Vinh, Pham Nguyen, Schou, Morten, Tereshchenko, Sergey, Køber, Lars, Kosiborod, Mikhail N., Langkilde, Anna Maria, Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D., Johanson, Per, Greasley, Peter J., Boulton, David, Bengtsson, Olof, Jhund, Pardeep S., McMurray, John J.V., Petrie, Mark C., Verma, Subodh, Docherty, Kieran F., Inzucchi, Silvio E., Anand, Inder, Bělohlávek, Jan, Böhm, Michael, Chiang, Chern En, Chopra, Vijay K., De Boer, Rudolf A., Desai, Akshay S., Diez, Mirta, Drozdz, Jaroslaw, Dukát, Andre, Ge, Junbo, Howlett, Jonathan, Katova, Tzvetana, Kitakaze, Masafumi, Ljungman, Charlotta E.A., Merkely, Béla, Nicolau, Jose C., O'Meara, Eileen, Vinh, Pham Nguyen, Schou, Morten, Tereshchenko, Sergey, Køber, Lars, Kosiborod, Mikhail N., Langkilde, Anna Maria, Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D., Johanson, Per, Greasley, Peter J., Boulton, David, Bengtsson, Olof, Jhund, Pardeep S., and McMurray, John J.V.

Abstract

Importance: Additional treatments are needed for heart failure with reduced ejection fraction (HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment for patients with HFrEF, even those without diabetes. Objective: To evaluate the effects of dapagliflozin in patients with HFrEF with and without diabetes. Design, Setting, and Participants: Exploratory analysis of a phase 3 randomized trial conducted at 410 sites in 20 countries. Patients with New York Heart Association classification II to IV with an ejection fraction less than or equal to 40% and elevated plasma N-terminal pro B-type natriuretic peptide were enrolled between February 15, 2017, and August 17, 2018, with final follow-up on June 6, 2019. Interventions: Addition of once-daily 10 mg of dapagliflozin or placebo to recommended therapy. Main Outcomes and Measures: The primary outcome was the composite of an episode of worsening heart failure or cardiovascular death. This outcome was analyzed by baseline diabetes status and, in patients without diabetes, by glycated hemoglobin level less than 5.7% vs greater than or equal to 5.7%. Results: Among 4744 patients randomized (mean age, 66 years; 1109 [23%] women; 2605 [55%] without diabetes), 4742 completed the trial. Among participants without diabetes, the primary outcome occurred in 171 of 1298 (13.2%) in the dapagliflozin group and 231 of 1307 (17.7%) in the placebo group (hazard ratio, 0.73 [95% CI, 0.60-0.88]). In patients with diabetes, the primary outcome occurred in 215 of 1075 (20.0%) in the dapagliflozin group and 271 of 1064 (25.5%) in the placebo group (hazard ratio, 0.75 [95% CI, 0.63-0.90]) (P value for interaction =.80). Among patients without diabetes and a glycated hemoglobin level less than 5.7%, the primary outcome occurred in 53 of 438 patients (12.1%) in the dapagliflozin group and 71 of 419 (16.9%) in the placebo group (hazard ratio, 0.67 [95% CI, 0.47-0.96]). In patients with a glycated hemoglobin of at

Published
2020

24. Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines

Author

Marston, Nicholas A., primary, Bonaca, Marc P., additional, Jarolim, Petr, additional, Goodrich, Erica L., additional, Bhatt, Deepak L., additional, Steg, Philippe G., additional, Cohen, Marc, additional, Storey, Robert F., additional, Johanson, Per, additional, Wiviott, Stephen D., additional, Braunwald, Eugene, additional, Sabatine, Marc S., additional, and Morrow, David A., additional

Published
2020
Full Text
View/download PDF

27. 'Mirror-lake' serial relationship of Electrocardiographic and biochemical indices for the detection of reperfusion and the predidtion of salvage in patients with acute myocardial infarction

Author

Jurlander, Birgit, Holmvang, Lene, Galatius, Soren, Vaught, Creighton, Johanson, Per, Krucoff, Mitchell W., Grande, Peer, Clemmensen, Peter, and Wanger, Galen S.

Subjects
Heart attack -- Diagnosis, Reperfusion (Physiology) -- Diagnosis, Electrocardiogram -- Usage, Electrocardiography -- Usage, Health
Published
2003

30. Third universal definition of myocardial infarction

Author

Thygesen, Kristian, Alpert, Joseph S., Jaffe, Allan S., Simoons, Maarten L., Chaitman, Bernard R., White, Harvey D., Thygesen, Kristian, Alpert, Joseph S., White, Harvey D., Jaffe, Allan S., Katus, Hugo A., Apple, Fred S., Lindahl, Bertil, Morrow, David A., Chaitman, Bernard R., Clemmensen, Peter M., Johanson, Per, Hod, Hanoch, Underwood, Richard, Bax, Jeroen J., Bonow, Robert O., Pinto, Fausto, Gibbons, Raymond J., Fox, Keith A., Atar, Dan, Newby, L. Kristin, Galvani, Marcello, Hamm, Christian W., Uretsky, Barry F., Gabriel Steg, Ph., Wijns, William, Bassand, Jean-Pierre, Menasché, Phillippe, Ravkilde, Jan, Ohman, E. Magnus, Antman, Elliott M., Wallentin, Lars C., Armstrong, Paul W., Simoons, Maarten L., Januzzi, James L., Nieminen, Markku S., Gheorghiade, Mihai, Filippatos, Gerasimos, Luepker, Russell V., Fortmann, Stephen P., Rosamond, Wayne D., Levy, Dan, Wood, David, Smith, Sidney C., Hu, Dayi, Lopez-Sendon, José-Luis, Robertson, Rose Marie, Weaver, Douglas, Tendera, Michal, Bove, Alfred A., Parkhomenko, Alexander N., Vasilieva, Elena J., Mendis, Shanti, Bax, Jeroen J., Baumgartner, Helmut, Ceconi, Claudio, Dean, Veronica, Deaton, Christi, Fagard, Robert, Funck-Brentano, Christian, Hasdai, David, Hoes, Arno, Kirchhof, Paulus, Knuuti, Juhani, Kolh, Philippe, McDonagh, Theresa, Moulin, Cyril, Popescu, Bogdan A., Reiner, Željko, Sechtem, Udo, Sirnes, Per Anton, Tendera, Michal, Torbicki, Adam, Vahanian, Alec, Windecker, Stephan, Morais, Joao, Aguiar, Carlos, Almahmeed, Wael, Arnar, David O., Barili, Fabio, Bloch, Kenneth D., Bolger, Ann F., Bøtker, Hans Erik, Bozkurt, Biykem, Bugiardini, Raffaele, Cannon, Christopher, de Lemos, James, Eberli, Franz R., Escobar, Edgardo, Hlatky, Mark, James, Stefan, Kern, Karl B., Moliterno, David J., Mueller, Christian, Neskovic, Aleksandar N., Pieske, Burkert Mathias, Schulman, Steven P., Storey, Robert F., Taubert, Kathryn A., Vranckx, Pascal, and Wagner, Daniel R.

Published
2012
Full Text
View/download PDF

31. Continuous ST monitoring: a bedside instrument?

Author

Johanson, per, Rossberg, Jenny, and Dellborg, Mikael

Subjects
Patient monitoring -- Evaluation, Heart attack -- Care and treatment, Cardiac patients -- Care and treatment, Health
Published
2001

34. Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS‐TIMI 54 Trial

Author

Furtado, Remo H. M., primary, Venkateswaran, Ramkumar V., additional, Nicolau, Jose C., additional, Gurmu, Yared, additional, Bhatt, Deepak L., additional, Storey, Robert F., additional, Steg, P. Gabriel, additional, Magnani, Giuglia, additional, Goto, Shinya, additional, Dellborg, Mikael, additional, Kamensky, Gabriel, additional, Isaza, Daniel, additional, Aylward, Philip, additional, Johanson, Per, additional, and Bonaca, Marc P., additional

Published
2020
Full Text
View/download PDF

35. Gut Microbiota‐Dependent Trimethylamine N‐oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS‐TIMI 54 Trial

Author

Gencer, Baris, primary, Li, Xinmin S., additional, Gurmu, Yared, additional, Bonaca, Marc P., additional, Morrow, David A., additional, Cohen, Marc, additional, Bhatt, Deepak L., additional, Steg, P. Gabriel, additional, Storey, Robert F., additional, Johanson, Per, additional, Wang, Zeneng, additional, Hazen, Stanley L., additional, and Sabatine, Marc S., additional

Published
2020
Full Text
View/download PDF

36. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

Author

Petrie, Mark C., primary, Verma, Subodh, additional, Docherty, Kieran F., additional, Inzucchi, Silvio E., additional, Anand, Inder, additional, Belohlávek, Jan, additional, Böhm, Michael, additional, Chiang, Chern-En, additional, Chopra, Vijay K., additional, de Boer, Rudolf A., additional, Desai, Akshay S., additional, Diez, Mirta, additional, Drozdz, Jaroslaw, additional, Dukát, Andre, additional, Ge, Junbo, additional, Howlett, Jonathan, additional, Katova, Tzvetana, additional, Kitakaze, Masafumi, additional, Ljungman, Charlotta E. A., additional, Merkely, Béla, additional, Nicolau, Jose C., additional, O'Meara, Eileen, additional, Vinh, Pham Nguyen, additional, Schou, Morten, additional, Tereshchenko, Sergey, additional, Køber, Lars, additional, Kosiborod, Mikhail N., additional, Langkilde, Anna Maria, additional, Martinez, Felipe A., additional, Ponikowski, Piotr, additional, Sabatine, Marc S., additional, Sjöstrand, Mikaela, additional, Solomon, Scott D., additional, Johanson, Per, additional, Greasley, Peter J., additional, Boulton, David, additional, Bengtsson, Olof, additional, Jhund, Pardeep S., additional, and McMurray, John J. V., additional

Published
2020
Full Text
View/download PDF

38. Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54

Author

Furtado, Remo H M, primary, Nicolau, Jose C, additional, Magnani, Giulia, additional, Im, Kyungah, additional, Bhatt, Deepak L, additional, Storey, Robert F, additional, Steg, P Gabriel, additional, Spinar, Jindrich, additional, Budaj, Andrzej, additional, Kontny, Frederic, additional, Corbalan, Ramon, additional, Kiss, Robert G, additional, Abola, Maria Teresa, additional, Johanson, Per, additional, Jensen, Eva C, additional, Braunwald, Eugene, additional, Sabatine, Marc S, additional, and Bonaca, Marc P, additional

Published
2019
Full Text
View/download PDF

39. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes.

Author

Berg, David D., Wiviott, Stephen D., Scirica, Benjamin M., Zelniker, Thomas A., Goodrich, Erica L., Jarolim, Petr, Mosenzon, Ofri, Cahn, Avivit, Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P.H., Johanson, Per, Langkilde, Anna Maria, Raz, Itamar, Braunwald, Eugene, Sabatine, Marc S., and Morrow, David A.

Subjects
HEART failure patients, PEOPLE with diabetes, TYPE 2 diabetes, MYOCARDIAL infarction, TREATMENT effectiveness, RESEARCH, RESEARCH methodology, EVALUATION research, RISK assessment, COMPARATIVE studies, HOSPITAL care, RESEARCH funding, HEART failure, DISEASE complications
Abstract

Objective: Heart failure (HF) is an impactful complication of type 2 diabetes mellitus (T2DM). We aimed to develop and validate a risk score for hospitalization for HF (HHF) incorporating biomarkers and clinical factor(s) in patients with T2DM.Research Design and Methods: We derived a risk score for HHF using clinical data, high-sensitivity troponin T (hsTnT), and N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) from 6,106 placebo-treated patients with T2DM in SAVOR-TIMI 53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53). Candidate variables were assessed using Cox regression. The strongest indicators of HHF risk were included in the score using integer weights. The score was externally validated in 7,251 placebo-treated patients in DECLARE-TIMI 58 (Dapagliflozin Effect on CardiovascuLAR Events-Thrombolysis in Myocardial Infarction 58). The effect of dapagliflozin on HHF was assessed by risk category in DECLARE-TIMI 58.Results: The strongest indicators of HHF risk were NT-proBNP, prior HF, and hsTnT (each P < 0.001). A risk score using these three variables identified a gradient of HHF risk (P-trend <0.001) in the derivation and validation cohorts, with C-indices of 0.87 (95% CI, 0.84-0.89) and 0.84 (0.81-0.86), respectively. Whereas there was no significant effect of dapagliflozin versus placebo on HHF in the low-risk group (hazard ratio [HR] 0.98 [95% CI 0.50-1.92]), dapagliflozin significantly reduced HHF in the intermediate-, high-, and very-high-risk groups (HR 0.64 [0.43-0.95], 0.63 [0.43-0.94], and 0.72 [0.54-0.96], respectively). Correspondingly, absolute risk reductions (95% CI) increased across these latter 3 groups: 1.0% (0.0-1.9), 3.0% (0.7-5.3), and 4.4% (-0.2 to 8.9) (P-trend <0.001).Conclusions: We developed and validated a risk score for HHF in T2DM that incorporated NT-proBNP, prior HF, and hsTnT. The risk score identifies patients at higher risk of HHF who derive greater absolute benefit from dapagliflozin. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

44. Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54

Author

Bonaca, Marc P, Wiviott, Stephen D, Morrow, David A, Steg, P Gabriel, Hamm, Christian, Bhatt, Deepak L, Storey, Robert F, Cohen, Marc, Kuder, Julia, Im, KyungAh, Magnani, Giulia, Budaj, Andrzej, Nicolau, José C, Parkhomenko, Alexander, López-Sendón, José, Dellborg, Mikael, Diaz, Rafael, Van de Werf, Frans, Corbalán, Ramón, Goudev, Assen, Jensen, Eva C, Johanson, Per, Braunwald, Eugene, and Sabatine, Marc S

Subjects
myocardial infarction, troponin, ST‐segment elevation myocardial infarction, antiplatelet therapy, ticagrelor
Abstract

Background Ticagrelor reduced cardiovascular death, myocardial infarction (MI), or stroke in patients with prior MI in PEGASUS-TIMI 54 (Prevention of Cardiovascular Events [eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke] in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin). MI can occur in diverse settings and with varying severity; therefore, understanding the types and sizes of MI events prevented is of clinical importance. Methods and Results MIs were adjudicated by a blinded clinical events committee and categorized by subtype and fold elevation of peak cardiac troponin over the upper limit of normal. A total of 1042 MIs occurred in 898 of the 21 162 randomized patients over a median follow-up of 33 months. The majority of the MIs (76%) were spontaneous (Type 1), with demand MI (Type 2) and stent thrombosis (Type 4b) accounting for 13% and 9%, respectively; sudden death (Type 3), percutaneous coronary intervention-related (Type 4a) and coronary artery bypass graft-related (Type 5) each accounted for

Published
2018

45. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54

Author

Dellborg, Mikael, primary, Bonaca, Marc P, additional, Storey, Robert F, additional, Steg, P Gabriel, additional, Im, Kyung A, additional, Cohen, Marc, additional, Bhatt, Deepak L, additional, Oude Ophuis, Ton, additional, Budaj, Andrezej, additional, Hamm, Christian, additional, Spinar, Jindrich, additional, Kiss, Robert G, additional, Lopez-Sendon, José, additional, Kamensky, Gabriel, additional, Van de Werf, Frans, additional, Ardissino, Diego, additional, Kontny, Frederic, additional, Montalescot, Gilles, additional, Johanson, Per, additional, Bengtsson, Olof, additional, Himmelmann, Anders, additional, Braunwald, Eugene, additional, and Sabatine, Marc S, additional

Published
2019
Full Text
View/download PDF

46. Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54

Author

Bonaca, Marc P., primary, Wiviott, Stephen D., additional, Morrow, David A., additional, Steg, P. Gabriel, additional, Hamm, Christian, additional, Bhatt, Deepak L., additional, Storey, Robert F., additional, Cohen, Marc, additional, Kuder, Julia, additional, Im, KyungAh, additional, Magnani, Giulia, additional, Budaj, Andrzej, additional, Nicolau, José C., additional, Parkhomenko, Alexander, additional, López‐Sendón, José, additional, Dellborg, Mikael, additional, Diaz, Rafael, additional, Van de Werf, Frans, additional, Corbalán, Ramón, additional, Goudev, Assen, additional, Jensen, Eva C., additional, Johanson, Per, additional, Braunwald, Eugene, additional, and Sabatine, Marc S., additional

Published
2018
Full Text
View/download PDF

47. Improvements in hip arthroplasty - did they work? Evaluations of different articulations and fixation concepts

Author

Johanson, Per-Erik

Subjects
outcome, hip arthroplasty, innovation
Abstract

Today, total hip arthroplasty (THA) is one of the safest and most efficient surgical treatments. New materials, surgical techniques and design concepts intended to improve THA have not always been successful. Thorough preclinical and early clinical investigations can detect some aspects of under-performing, while continuing surveillance is recommended to detect and analyze reasons for any later appearing flaws. In this thesis, several ways to monitor and assess THA performance are explored and carried out, using survival analysis in registry studies, radiostereometry (RSA), radiology and clinical outcome. In Paper I, a study using the Nordic Arthroplasty Register Association (NARA) registry shows that HRA had an almost 3-fold increased early non-septic revision risk and that risk factors were found to be female sex, certain HRA designs and units having performed few HRA procedures. Papers II and III contain comparisons of highly cross-linked polyethylene (XLPE) and conventional polyethylene (PE). XLPE had a considerably lower wear rate up to 10 years but showed no obvious improvements regarding implant fixation, BMD or clinical outcome. In the NARA registry, in 2 of 4 studied cup designs the XLPE version had a lower risk of revision for aseptic loosening compared to the PE version. Paper IV describes that stem subsidence and retrotorsion measured with RSA at 2 years predicted later aseptic stem failure in an unfavorably altered, previously well-functioning cemented femoral stem. In Paper V and VI, a novel approach to measure articulation wear with RSA in radiodense hip arthroplasty articulations was presented and evaluated. Subsequently, a comparison between ceramic-on-ceramic (COC) and metal-on-conventional PE uncemented THA displayed a considerably lower wear rate, smaller periacetabular bone lesions and a relatively high squeaking rate, the latter with unknown long-term consequences, in the COC hips. Implant fixation, heterotopic ossification and clinical outcome did not differ between articulation types. In conclusion, it was confirmed that implant surveillance can be done with RSA, also in radiodense THA. Early migration predicts later aseptic implant failure. Prolonged surveillance can confirm long-term material and design performance, verify or contradict anticipated advantages as well as detect unanticipated long-term complications.

Published
2017

48. Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54.

Author

Furtado, Remo H M, Nicolau, Jose C, Magnani, Giulia, Im, Kyungah, Bhatt, Deepak L, Storey, Robert F, Steg, P Gabriel, Spinar, Jindrich, Budaj, Andrzej, Kontny, Frederic, Corbalan, Ramon, Kiss, Robert G, Abola, Maria Teresa, Johanson, Per, Jensen, Eva C, Braunwald, Eugene, Sabatine, Marc S, and Bonaca, Marc P

Abstract

Aims PEGASUS-TIMI 54 demonstrated that long-term dual antiplatelet therapy (DAPT) with aspirin and ticagrelor reduced the risk of major adverse cardiovascular events (MACE), with an acceptable increase in bleeding, in patients with prior myocardial infarction (MI). While much of the discussion around prolonged DAPT has been focused on stented patients, patients with prior MI without prior coronary stenting comprise a clinically important subgroup. Methods and results This was a pre-specified analysis from PEGASUS-TIMI 54, which randomized 21 162 patients with prior MI (1–3 years) and additional high-risk features to ticagrelor 60 mg, 90 mg, or placebo twice daily in addition to aspirin. A total of 4199 patients had no history of coronary stenting at baseline. The primary efficacy outcome (MACE) was the composite of cardiovascular death, MI, or stroke. Patients without history of coronary stenting had higher baseline risk of MACE [13.2% vs. 8.0%, adjusted hazard ratio (HR) 1.41, 95% confidence interval (CI) 1.15–1.73, in the placebo arm]. The relative risk reduction in MACE with ticagrelor (pooled doses) was similar in patients without (HR 0.82, 95% CI 0.68–0.99) and with prior stenting (HR 0.85, 95% CI 0.75–0.96; P for interaction = 0.76). Conclusion Long-term ticagrelor reduces thrombotic events in patients with prior MI regardless of whether they had prior coronary stenting. These data highlight the benefits of DAPT in prevention of spontaneous atherothrombotic events and indicate that long-term ticagrelor may be considered in high-risk patients with prior MI even if they have not been treated with stenting. ClinicalTrials.gov Identifier NCT01225562. Open in new tab Download slide Open in new tab Download slide [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

50. Decreased admissions and hospital costs with a neutral effect on mortality following lowering of the troponin T cutoff point to the 99th percentile

Author

Bjurman, Christian, Zywczyk, Matteus, Lindahl, Bertil, Carlsson, Tobias, Johanson, Per, Petzold, Max, Holzmann, Martin, Fu, Michael L. X., Hammarsten, Ola, Bjurman, Christian, Zywczyk, Matteus, Lindahl, Bertil, Carlsson, Tobias, Johanson, Per, Petzold, Max, Holzmann, Martin, Fu, Michael L. X., and Hammarsten, Ola

Abstract

Background: The implementation of high-sensitivity cardiac troponin T (hs-cTnT) assays and a cutoff based on the 99th cTnT percentile in the evaluation of patients with suspected acute coronary syndrome has not been uniform due to uncertain effects on health benefits and utilization of limited resources. Methods: Clinical and laboratory data from patients with chest pain or dyspnea at the emergency department (ED) were evaluated before (n = 20516) and after (n = 18485) the lowering of the hs-cTnT cutoff point from 40 ng/L to the 99th hs-cTnT percentile of 14 ng/L in February 2012. Myocardial infarction (MI) was diagnosed at the discretion of the attending clinicians responsible for the patient. Results: Following lowering of the hs-cTnT cutoff point fewer ED patients with chest pain or dyspnea as the principal complaint were analyzed with an hs-cTnT sample (81% vs. 72%, p < 0.001). Overall 30-day mortality was unaffected but increased among patients not analyzed with an hs-cTnT sample (5.3% vs. 7.6%, p < 0.001). The MI frequency was unchanged (4.0% vs. 3.9%, p = 0.72) whereas admission rates decreased (51% vs. 45%, p < 0.001) as well as hospital costs. Coronary angiographies were used more frequently (2.8% vs. 3.3%, p = 0.004) but with no corresponding change in coronary interventions. Conclusions: At the participating hospital, lowering of the hs-cTnT cutoff point to the 99th percentile decreased admissions and hospital costs but did not result in any apparent prognostic or treatment benefits for the patients.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results